HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease

Kidney International

Volumn 90, Issue 5, 2016, Pages 923-925

  Wyatt, Christina M ^a   Drüeke, Tilman B ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DAPRODUSTAT; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; VADADUSTAT; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

ANEMIA; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; NOTE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; COMPLICATION;

ANEMIA; HEMATINICS; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84994189061     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.08.016     Document Type: Note

References (9)

1. 1 Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
2. 2 Singh, A.K., Szczech, L., Tang, K.L., et al., for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
3. 3 Zumbrennen-Bullough, K., Babitt, J.L., The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 29 (2014), 263–273.
4. 4 Maxwell, P.H., Eckhardt, K.U., HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 12 (2016), 157–168.
5. 5 Provenzano, R., Besarab, A., Sun, C.H., et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 11 (2016), 982–991.
6. 6 Provenzano, R., Besarab, A., Wright, S., et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67 (2016), 912–924.
7. 7 Besarab, A., Chernyavskaya, E., Motylev, I., et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27 (2016), 1225–1233.
8. 8 Holdstock, L., Meadowcroft, A.M., Maier, R., et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27 (2016), 1234–1244.
9. 9 Pergola, P.E., Spinowitz, B.S., Hartman, C.S., et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90 (2016), 1115–1122.